Keith T Flaherty

Keith T Flaherty

UNVERIFIED PROFILE

Are you Keith T Flaherty?   Register this Author

Register author
Keith T Flaherty

Keith T Flaherty

Publications by authors named "Keith T Flaherty"

Are you Keith T Flaherty?   Register this Author

100Publications

8374Reads

34Profile Views

Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways.

Nat Rev Clin Oncol 2019 Sep;16(9):549-562

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0204-6DOI Listing
September 2019

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.

N Engl J Med 2019 08 4;381(7):626-636. Epub 2019 Jun 4.

From Institut Gustave Roussy and Paris-Sud-Paris-Saclay University, Villejuif (C.R.), Aix-Marseille University, Marseille (J.J.G.), and Assistance Publique-Hôpitaux de Paris Dermatology and Clinical Investigation Center, Unité 976, Université de Paris, Hôpital Saint-Louis, Paris (C.L.) - all in France; Moscow City Oncology Hospital, Moscow (D. Stroyakovskiy), and the Petrov Research Institute of Oncology, St. Petersburg (E.L.) - both in Russia; Przychodnia Lekarska Komed, Konin (B.K.), the University of Medical Sciences, Poznań (A.M.), and the Maria Skłodowska-Curie Institute-Oncology Center, Warsaw (P.R.) - all in Poland; the University Hospital Schleswig-Holstein, Kiel (A.H.), the Department of Dermatology, University of Tübingen, Tübingen (C.G.), University Hospital Essen, Essen (D. Schadendorf), and the German Cancer Consortium, Heidelberg (D. Schadendorf) - all in Germany; the Veneto Institute of Oncology, Padua (V.C.S.), and Papa Giovanni XXIII Hospital, Bergamo (M.M.) - both in Italy; the Ella Lemelbaum Institute for Immuno-Oncology and Melanoma, Sheba Medical Center, Tel Hashomer (J.S.), and Sackler Medical School, Tel Aviv University, Tel Aviv (J.S.) - both in Israel; Dnipropetrovsk State Medical Academy, Dnipropetrovsk, Ukraine (I.B.); Laiko General Hospital, National and Kapodistrian University of Athens School of Medicine, Athens (H.G.); the Netherlands Cancer Institute, Amsterdam (J.B.A.G.H.); Mount Vernon Cancer Centre, Northwood, United Kingdom (P.D.N.); the University of California, Los Angeles, Los Angeles (A.R.); the University of Texas M.D. Anderson Cancer Center, Houston (M.A.D.); Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston (K.T.F.); Novartis Pharma, Basel, Switzerland (P.B.); Novartis Pharmaceuticals, East Hanover, NJ (M.T., E.G., M.V.); and the Melanoma Institute Australia, the University of Sydney, and Royal North Shore and Mater Hospitals, Sydney (G.V.L.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1904059DOI Listing
August 2019

A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITF /AXL melanoma.

Pigment Cell Melanoma Res 2019 03 19;32(2):280-291. Epub 2018 Oct 19.

Manchester Cancer Research Centre, Faculty of Biology, Medicine & Health, Division of Cancer Sciences, The University of Manchester, Manchester, UK.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/pcmr.12741
Publisher Site
http://dx.doi.org/10.1111/pcmr.12741DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6392120PMC
March 2019

Response to Immune Checkpoint Antibodies: Not All Responses Are Created Equal.

Clin Cancer Res 2019 Feb 3;25(3):910-911. Epub 2018 Dec 3.

Department of Medicine, Division of Medical Oncology, Massachusetts General Hospital Cancer Center, Center for Melanoma, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-18-3296DOI Listing
February 2019

When Tissue Is No Longer the Issue: Tissue-Agnostic Cancer Therapy Comes of Age.

Ann Intern Med 2018 08 24;169(4):233-239. Epub 2018 Jul 24.

Massachusetts General Hospital Cancer Center, Boston, Massachusetts (K.T.F.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7326/M17-2832DOI Listing
August 2018

The impact of timing of immunotherapy with cranial irradiation in melanoma patients with brain metastases: intracranial progression, survival and toxicity.

J Neurooncol 2018 Jun 16;138(2):299-306. Epub 2018 Feb 16.

Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 30 Fruit Street, Boston, MA, 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-018-2795-7DOI Listing
June 2018

Anti-PD-1 antibody treatment for melanoma.

Lancet Oncol 2018 05;19(5):e219

Massachusetts General Hospital Cancer Center, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30202-XDOI Listing
May 2018

Immune Checkpoint Inhibitor Cancer Therapy: Spectrum of Imaging Findings.

Radiographics 2017 Nov-Dec;37(7):2132-2144

From the Departments of Radiology (G.X.W., V.K., S.I.L., F.J.F.) and Medicine (J.F.G., R.J.S., K.T.F.), Massachusetts General Hospital, Harvard Medical School, 55 Fruit St, Founders 210, Boston, MA 02114.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1148/rg.2017170085DOI Listing
April 2018

Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.

J Clin Oncol 2018 03 9;36(7):667-673. Epub 2017 Oct 9.

Georgina V. Long, University of Sydney, and Royal North Shore Hospital; Richard Kefford, Macquarie University, Sydney, and Westmead Hospital, Westmead, New South Wales; Jonathan Cebon, Ludwig Institute for Cancer Research, Melbourne, Victoria, Australia; Zeynep Eroglu, Moffitt Cancer Center, Tampa, FL; Jeffrey Infante, Tennessee Oncology; Douglas B. Johnson, Vanderbilt-Ingram Cancer Center, Nashville, TN; Sapna Patel, The University of Texas MD Anderson Cancer Center, Houston, TX; Adil Daud, University of California, San Francisco, San Francisco; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles, CA; Rene Gonzalez, University of Colorado, Denver, CO; Lynn Schuchter, University of Pennsylvania, Philadelphia, PA; William Sharfman, Sidney Kimmel Cancer Center, Baltimore, MD; Robert McWilliams, Mayo Clinic, Rochester, MN; Mario Sznol, Yale University, New Haven, CT; Suman Redhu, Eduard Gasal, and Bijoyesh Mookerjee, Novartis, East Hanover, NJ; Jeffrey Weber, New York University Langone Medical Center, New York, NY; and Keith T. Flaherty, Dana-Farber/Harvard Cancer Center, Boston, MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.74.1025
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.74.1025DOI Listing
March 2018

Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids.

Cancer Discov 2018 02 3;8(2):196-215. Epub 2017 Nov 3.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-17-0833DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5809290PMC
February 2018

Melanoma in 2017: Moving treatments earlier to move further forwards.

Nat Rev Clin Oncol 2018 02 28;15(2):75-76. Epub 2017 Nov 28.

Center for Targeted Therapies, Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, Massachusetts 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2017.183DOI Listing
February 2018

Mechanisms of resistance to immune checkpoint inhibitors.

Br J Cancer 2018 01 2;118(1):9-16. Epub 2018 Jan 2.

Division of Medical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/bjc.2017.434DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765236PMC
January 2018

Tissue-Agnostic Drug Development.

Am Soc Clin Oncol Educ Book 2017 ;37:222-230

From the Massachusetts General Hospital Cancer Center, Boston, MA; The Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD; Office of Hematology and Oncology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_173855DOI Listing
December 2017

PDL1 expression in desmoplastic melanoma is associated with tumor aggressiveness and progression.

J Am Acad Dermatol 2017 Sep 18;77(3):534-542. Epub 2017 Jul 18.

Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2017.05.007DOI Listing
September 2017

Harnessing Research Discoveries to Save Lives.

Clin Cancer Res 2017 09;23(18):5325

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-17-2302DOI Listing
September 2017

Targeted agents and immunotherapies: optimizing outcomes in melanoma.

Nat Rev Clin Oncol 2017 Aug 4;14(8):463-482. Epub 2017 Apr 4.

Melanoma Institute Australia, The University of Sydney, and The Mater Hospital, Rocklands Road, North Sydney, New South Wales 2060, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2017.43DOI Listing
August 2017

Oncogenic RAS Regulates Long Noncoding RNA in Human Cancer.

Cancer Res 2017 07 4;77(14):3745-3757. Epub 2017 May 4.

Center for Research on Reproduction & Women's Health, Department of Obstetrics and Gynecology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-16-1768DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5511552PMC
July 2017

An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition.

J Exp Med 2017 06 27;214(6):1691-1710. Epub 2017 Apr 27.

Manchester Cancer Research Centre, Faculty of Biology, Medicine, and Health, School of Medical Sciences, Division of Molecular and Clinical Cancer Studies, The University of Manchester, Manchester M13 9PT, England, UK

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1084/jem.20160855DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460994PMC
June 2017

Parallel In Vivo Assessment of Drug Phenotypes at Various Time Points during Systemic BRAF Inhibition Reveals Tumor Adaptation and Altered Treatment Vulnerabilities.

Clin Cancer Res 2016 Dec 18;22(24):6031-6038. Epub 2016 Apr 18.

David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-2722DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5320949PMC
December 2016

Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma.

Clin Cancer Res 2016 Sep 13;22(17):4452-65. Epub 2016 Apr 13.

Department of Neurosurgery, Translational Neuro-Oncology Laboratory, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-2274DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010492PMC
September 2016

Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.

Nat Med 2016 09 8;22(9):1056-61. Epub 2016 Aug 8.

Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm.4155DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5014622PMC
September 2016

Ki-67, p53, and p16 expression, and G691S RET polymorphism in desmoplastic melanoma (DM): A clinicopathologic analysis of predictors of outcome.

J Am Acad Dermatol 2016 Sep;75(3):595-602

Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2016.04.059DOI Listing
September 2016

High-Throughput Testing of Novel-Novel Combination Therapies for Cancer: An Idea Whose Time Has Come.

Cancer Discov 2016 09;6(9):956-62

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-16-0440DOI Listing
September 2016

The Conundrum of Genetic "Drivers" in Benign Conditions.

J Natl Cancer Inst 2016 08 7;108(8). Epub 2016 Apr 7.

Department of Investigational Cancer Therapeutics, MD Anderson Cancer Center, Houston, TX (SK); Center for Personalized Cancer Therapy and Division of Hematology and Oncology, UC San Diego Moores Cancer Center, La Jolla, CA (SML, RK); Henri and Belinda Termeer Center for Targeted Therapies, Massachusetts General Hospital Cancer Center, Boston, MA (KTF).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw036DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5017937PMC
August 2016

Subretinal Fluid Associated With MEK Inhibitor Use in the Treatment of Systemic Cancer.

JAMA Ophthalmol 2016 Aug;134(8):855-62

Ophthalmic Consultants of Boston, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaophthalmol.2016.0090DOI Listing
August 2016

A novel multi-CDK inhibitor P1446A-05 restricts melanoma growth and produces synergistic effects in combination with MAPK pathway inhibitors.

Cancer Biol Ther 2016 07;17(7):778-84

a Wellman Center for Photomedicine and Department of Dermatology, Massachusetts General Hospital, Harvard Medical School , Boston , MA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15384047.2016.1139267DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4970529PMC
July 2016

Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment.

PLoS One 2015 13;10(10):e0140310. Epub 2015 Oct 13.

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, United States of America; Dermatology and Cutaneous Biology Research Center, Massachusetts General Hospital, Charlestown, Massachusetts, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0140310PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604168PMC
June 2016

Biomarkers in Melanoma: Lessons from Translational Medicine.

Trends Cancer 2016 06 2;2(6):305-312. Epub 2016 Jun 2.

Department of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.trecan.2016.05.003DOI Listing
June 2016

Promoter Methylation of PTEN Is a Significant Prognostic Factor in Melanoma Survival.

J Invest Dermatol 2016 05 15;136(5):1002-1011. Epub 2016 Feb 15.

Wellman Center for Photomedicine, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jid.2016.01.024DOI Listing
May 2016

Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance.

Cancer Discov 2016 Apr 16;6(4):382-99. Epub 2016 Mar 16.

Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts. David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts. Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5087317PMC
http://dx.doi.org/10.1158/2159-8290.CD-15-0933DOI Listing
April 2016

Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.

J Clin Oncol 2016 Mar 25;34(8):871-8. Epub 2016 Jan 25.

Georgina V. Long, Melanoma Institute Australia; The University of Sydney; Richard F. Kefford, Melanoma Institute Australia; The University of Sydney; Macquarie University, Sydney; Westmead Hospital, Westmead; Jonathan Cebon, Austin Health, Melbourne, Victoria, Australia; Jeffrey S. Weber and Ragini Kudchadkar, Moffitt Cancer Center, Tampa, FL; Jeffrey R. Infante and Howard A. Burris III, Sarah Cannon Research Institute/Tennessee Oncology; Kevin B. Kim, California Pacific Medical Center; Adil Daud, Alain Algazi, University of California, San Francisco, San Francisco; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles, CA; Rene Gonzalez, Karl Lewis, University of Colorado; Gerald S. Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO; Jeffrey A. Sosman, Igor Puzanov, Vanderbilt University Medical Center, Nashville, TN; Lynn Schuchter, University of Pennsylvania Abramson Cancer Center; Nageatte Ibrahim, Elizabeth Cunningham, Merck; Peng Sun, Amy S. Kline, Heather Del Buono, Diane Opatt McDowell, GlaxoSmithKline, Philadelphia, PA; Donald Lawrence and Kiran Patel, Incyte Corporation, Wilmington, DE; and Keith T. Flaherty, Massachusetts General Hospital Cancer Center, Boston, MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2015.62.9345
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.62.9345DOI Listing
March 2016

Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy.

Cancer Cell 2016 Mar;29(3):270-284

Manchester Cancer Research Centre, Wellcome Trust Centre for Cell-Matrix Research, The University of Manchester, Michael Smith Building, Oxford Road, Manchester, M13 9PT, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2016.02.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4796027PMC
March 2016

Survival of patients with advanced metastatic melanoma: The impact of novel therapies.

Eur J Cancer 2016 Jan 17;53:125-34. Epub 2015 Dec 17.

Center for Dermatooncology, Department of Dermatology, University Tuebingen, 72074 Tuebingen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2015.09.013DOI Listing
January 2016

Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.

Oncotarget 2015 Dec;6(38):40535-56

Department of Biomedical Sciences and Cancer Biology Center, Texas Tech University Health Sciences Center, Amarillo, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.5755DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747351PMC
December 2015

Precision medicine for cancer with next-generation functional diagnostics.

Nat Rev Cancer 2015 Dec 5;15(12):747-56. Epub 2015 Nov 5.

Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit Street, Boston, Massachusetts 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrc4015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4970460PMC
December 2015

New drugs in development for melanoma.

Authors:
Keith T Flaherty

Clin Adv Hematol Oncol 2015 Nov;13(11):717-9

Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
November 2015